Clinical Trial Update: Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the combination of dalpiciclib and camrelizumab in hepatocellular carcinoma patients who have previously received imm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Dalpiciclib (dalpiciclib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellulcar Carcinoma | Phase 2 | Status: RECRUITING